For research use only. Not for therapeutic Use.
TCN 213 is a selective, surmountable, glycine-dependentlly GluN1/GluN2A NMDAR antagonist with IC50s of 0.55, 3.5, 40 μM in the presence of 75, 750, 7500 nM glycine, respectively. TCN 213 can be used to monitor, pharmacologically, the switch in NMDAR expression in developing cortical neurones[1][2].
TCN 213 (30 µM) antagonizes NMDA-evoked currents in neurones transfected with GluN2A subunits[1].
| Catalog Number | R042541 |
| CAS Number | 556803-08-8 |
| Synonyms | 2-[[5-(benzylamino)-1,3,4-thiadiazol-2-yl]sulfanyl]-N-(cyclohexylmethyl)acetamide |
| Molecular Formula | C18H24N4OS2 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H24N4OS2/c23-16(19-11-14-7-3-1-4-8-14)13-24-18-22-21-17(25-18)20-12-15-9-5-2-6-10-15/h2,5-6,9-10,14H,1,3-4,7-8,11-13H2,(H,19,23)(H,20,21) |
| InChIKey | XBAZPYFIYYCZBO-UHFFFAOYSA-N |
| SMILES | C1CCC(CC1)CNC(=O)CSC2=NN=C(S2)NCC3=CC=CC=C3 |
| Reference | [1]. McKay, S et al. “Direct pharmacological monitoring of the developmental switch in NMDA receptor subunit composition using TCN 213, a GluN2A-selective, glycine-dependent antagonist.” British journal of pharmacology vol. 166,3 (2012): 924-37. [2]. Edman S, et al. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-agonist dependent but non-competitive manner. Neuropharmacology. 2012 Sep;63(3):441-9. |
